Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. Nkarta has no approved products and generates no revenue. Its sole active program is NKX019, a CAR NK cell therapy targeting CD19, a protein expressed on B cells that drive autoimmune diseases like lupus nephritis, scleroderma, and myositis. NKX019 is currently in Phase 1 trials across multiple autoimmune indications. Nkarta's core value proposition is that NKX019 is allogeneic — manufactured in bulk from healthy donor cells and available on demand — unlike autologous CAR T therapies, which require custom manufacturing from each patient's own cells. Nkarta argues this off-the-shelf format offers several advantages: faster delivery, lower manufacturing costs spread across hundreds of doses per production run, a better safety profile (NK cells are less likely to cause the severe cytokine release syndrome and neurotoxicity associated with CAR T), and the potential for outpatient administration at a broader range of facilities. Nkarta manufactures clinical supply at its own facilities in South San Francisco. The company is funded by equity capital and spends primarily on R&D and clinical manufacturing. If NKX019 is approved, Nkarta's commercial model would follow the pattern of other cell therapies — a single-course, high-cost treatment reimbursed by insurers and government payors.